A. Dignass, G. Van-assche, and J. O. Lindsay, The second European evidencebased consensus on the diagnosis and management of Crohn's disease: current management, J Crohns Colitis, vol.4, pp.28-62, 2010.

A. Dignass, J. O. Lindsay, and A. Sturm, Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: current management, J Crohns Colitis, vol.6, pp.991-1030, 2012.

C. Mowat, A. Cole, and A. Windsor, Guidelines for the management of inflammatory bowel disease in adults, Gut, vol.60, pp.571-607, 2011.

J. F. Colombel and W. J. Sandborn, Reinisch RefeRences 1 Hansson gK, Inflammation HgK. Inflammation, atherosclerosis, and coronary artery disease, N Engl J Med, vol.352, pp.1685-95, 2005.

A. Shankar, J. Li, and F. J. Nieto, Association between C-reactive protein level and peripheral arterial disease among US adults without cardiovascular disease, diabetes, or hypertension, Am Heart J, vol.154, pp.495-501, 2007.

J. A. Avina-zubieta, J. Thomas, and M. Sadatsafavi, Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies, Ann Rheum Dis, vol.71, pp.1524-1533, 2012.

M. J. Peters, D. P. Symmons, and D. Mccarey, eUlAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis, Ann Rheum Dis, vol.69, pp.325-356, 2010.

D. P. Symmons and . Gabriel-se, epidemiology of CVD in rheumatic disease, with a focus on RA and Sle, Nat Rev Rheumatol, vol.7, pp.399-408, 2011.

S. Singh and H. Singh, Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis, Clin Gastroenterol Hepatol, vol.12, pp.382-93, 2014.

M. Fumery, C. Xiaocang, and . Dauchet-l, Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies, J Crohns Colitis, vol.8, pp.469-79, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01699623

C. Rungoe, S. Basit, and M. F. Ranthe, Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide danish cohort study, Gut, vol.62, pp.689-94, 2013.

C. N. Bernstein, A. Wajda, and J. F. Blanchard, The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study, Clin Gastroenterol Hepatol, vol.6, pp.41-46, 2008.

F. Andersohn and M. Waring, Risk of ischemic stroke in patients with Crohn's disease: a population-based nested case-control study, Inflamm Bowel Dis, vol.16, pp.1387-92, 2010.

C. Ha, S. Magowan, and N. A. Accortt, Risk of arterial thrombotic events in inflammatory bowel disease, Am J Gastroenterol, vol.104, pp.1445-51, 2009.

K. Sl, O. Ahlehoff, and J. Lindhardsen, Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death--a danish nationwide cohort study, PLoS One, vol.8, p.56944, 2013.

. Atih, Agence technique de l'information sur l'hospitalisation. Programme de médicalisation des systèmes d'information (PMSI, p.28, 2015.

, Répartition desDes décès selon le lieu duDu décès [Distribution of deaths according to location]: Institut national de la statistique et des études économiques, INSeeInstitut national de la statistique et des études économiques, p.28, 2014.

C. Ce, D. S. Rampton, and J. Rogers, Platelet aggregation and neutrophil sequestration in the mesenteric circulation in inflammatory bowel disease, Eur J Gastroenterol Hepatol, vol.9, pp.1213-1220, 1997.

O. A. Hatoum and B. Dg, The vasculature and inflammatory bowel disease: contribution to pathogenesis and clinical pathology, Inflamm Bowel Dis, vol.11, pp.304-317, 2005.

. Landesberg-g, W. S. Beattie, and M. Mosseri, Perioperative myocardial infarction, Circulation, vol.119, pp.2936-2980, 2009.

P. Rein, C. H. Saely, and . Silbernagel-g, Systemic inflammation is higher in peripheral artery disease than in stable coronary artery disease, Atherosclerosis, vol.239, pp.299-303, 2015.

S. Singh, I. J. Kullo, and D. S. Pardi, risk factors and management of cardiovascular diseases in IBD, Nat Rev Gastroenterol Hepatol, vol.12, pp.26-35, 2015.

R. X. Wu-gc,-leng and Q. Lu, Subclinical Atherosclerosis in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis, Angiology, vol.68, pp.447-61, 2017.

. Zanoli-l, M. Cannavò, and S. Rastelli, Arterial stiffness is increased in patients with inflammatory bowel disease, J Hypertens, vol.30, pp.1775-81, 2012.

I. Roifman, Y. C. Sun, and J. P. Fedwick, evidence of endothelial dysfunction in patients with inflammatory bowel disease, Clin Gastroenterol Hepatol, vol.7, pp.175-82, 2009.

. Fagan-ea, R. F. Dyck, and P. N. Maton, Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis, Eur J Clin Invest, vol.12, pp.351-360, 1982.

S. H. Saverymuttu, H. J. Hodgson, and V. S. Chadwick, Differing acute phase responses in Crohn's disease and ulcerative colitis, Gut, vol.27, pp.809-822, 1986.

M. Henriksen, J. Jahnsen, and I. Lygren, C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. results from a prospective population-based study, Gut, vol.57, pp.1518-1541, 2008.

V. Gross, T. Andus, and C. I. , evidence for continuous stimulation of interleukin-6 production in crohn's disease, Gastroenterology, vol.102, pp.514-523, 1992.

A. Oussalah, Peyrin-Biroulet l. Meta-analysis: hyperhomocysteinaemia in inflammatory bowel diseases, Aliment Pharmacol Ther, vol.34, pp.1173-84, 2011.

S. Saibeni, M. Cattaneo, and M. Vecchi, low vitamin B(6) plasma levels, a risk factor for thrombosis, in inflammatory bowel disease: role of inflammation and correlation with acute phase reactants, Am J Gastroenterol, vol.98, pp.112-119, 2003.

S. Galluzzo and P. G. Dicuonzo-g, Association between NOD2/CARD15 polymorphisms and coronary artery disease: a case-control study, Hum Immunol, vol.72, pp.636-676, 2011.

J. P. Hugot, P. Laurent-puig, and C. Gower-rousseau, Mapping of a susceptibility locus for crohn's disease on chromosome 16, Nature, vol.379, pp.821-824, 1996.

. Beaugerie-l, P. Seksik, and I. Nion-larmurier, Predictors of Crohn's disease, Gastroenterology, vol.130, pp.650-656, 2006.

S. P. Stowe, S. R. Redmond, and J. M. Stormont, An epidemiologic study of inflammatory bowel disease in Rochester, Gastroenterology, vol.98, pp.104-114, 1990.

. Loftus-cg, E. Loftus, and W. S. Harmsen, Update on the incidence and prevalence of crohn's disease and ulcerative colitis in Olmsted County, Inflamm Bowel Dis, vol.13, pp.254-61, 1940.

. Langholz-e, P. Munkholm, and M. Davidsen, Course of ulcerative colitis: analysis of changes in disease activity over years, Gastroenterology, vol.107, pp.3-11, 1994.

C. M. Couris, S. Polazzi, and F. Olive, Breast Cancer incidence using administrative data: correction with sensitivity and specificity, J Clin Epidemiol, vol.62, pp.660-666, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00428336

A. A. Chantry, C. Deneux-tharaux, and C. Cans, Hospital discharge data can be used for monitoring procedures and intensive care related to severe maternal morbidity, J Clin Epidemiol, vol.64, pp.1014-1036, 2011.
URL : https://hal.archives-ouvertes.fr/hal-02008104

Z. Uhry and M. Colonna, Cancer incidence estimation at a district level without a national registry: a validation study for 24 Cancer sites using french health insurance and registry data, Cancer Epidemiol, vol.37, pp.99-114, 2013.

J. Cottenet and . Molins-g, Outcomes after acute myocardial infarction in HIV-infected patients: analysis of data from a french nationwide hospital medical information database, Circulation, vol.127, pp.1767-74, 2013.

M. Sahli-l,-lapeyre-mestre and H. Derumeaux, Positive predictive values of selected hospital discharge diagnoses to identify infections responsible for hospitalization in the french national hospital database, Pharmacoepidemiol Drug Saf, vol.25, pp.785-794, 2016.

M. Giroud, M. Hommel, and . Benzenine-e, Positive predictive value of french hospitalization Discharge Codes for Stroke and transient ischemic attack, Eur Neurol, vol.74, pp.92-101, 2015.

, SPF. Les cardiopathies ischémiques. incidence: Santé Publique France, 2017.

P. Seksik, I. Nion-larmurier, and H. Sokol, effects of light smoking consumption on the clinical course of crohn's disease, Inflamm Bowel Dis, vol.15, pp.734-775, 2009.

N. Berthier, R. Richard, and J. , Regional comparison of tobacco smoking and e-cigarette use in France in 2014, Bull Epidémiol Hebd, vol.2016, pp.30508-3114

J. Kirchgesner, M. Rudnichi, and A. , Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the french administrative health databases, Aliment Pharmacol Ther, vol.45, pp.37-49, 2009.

, Age at cohort inclusion, mean (SD)

S. Singh, H. Singh, and L. Ev, Risk of Cerebrovascular Accidents and Ischemic Heart Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis, Clin Gastroenterol Hepatol, vol.12, pp.382-393, 2014.

J. Kirchgesner, L. Beaugerie, and F. Carrat, Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study, Gut, 2017.

G. K. Hansson, Inflammation, atherosclerosis, and coronary artery disease, N Engl J Med, vol.352, pp.1685-95, 2005.

J. A. Avina-zubieta, J. Thomas, and M. Sadatsafavi, Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies, Ann Rheum Dis, vol.71, pp.1524-1533, 2012.

M. Peters, D. Symmons, and D. Mccarey, EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis, Ann Rheum Dis, vol.69, pp.325-356, 2010.

D. Symmons and S. E. Gabriel, Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE, Nat Rev Rheumatol, vol.7, pp.399-408, 2011.

G. E. Mckellar, D. W. Mccarey, and N. Sattar, Role for TNF in atherosclerosis? Lessons from autoimmune disease, Nat Rev Cardiol, vol.6, p.57, 2009.

C. Rungoe, S. Basit, and M. F. Ranthe, Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study, Gut, vol.62, pp.689-94, 2013.

P. Tuppin, L. De-roquefeuil, and A. Weill, French national health insurance information system and the permanent beneficiaries sample, Rev DÉpidémiologie Santé Publique, vol.58, pp.286-90, 2010.

K. Bouillon, M. Bertrand, and G. Maura, Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study, Lancet Haematol, vol.2, pp.150-159, 2015.

F. Raguideau, M. Lemaitre, and R. Dray-spira, Association Between Oral Fluoroquinolone Use and Retinal Detachment, JAMA Ophthalmol, vol.134, p.415, 2016.

J. Kirchgesner, M. Lemaitre, and A. Rudnichi, Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases, Aliment Pharmacol Ther, vol.45, pp.37-49, 2009.

. Legifrance, Code de la santé publique -Article R5123-2

C. E. Collins, D. S. Rampton, and J. Rogers, Platelet aggregation and neutrophil sequestration in the mesenteric circulation in inflammatory bowel disease, Eur J Gastroenterol Hepatol, vol.9, pp.1213-1220, 1997.

O. A. Hatoum and D. G. Binion, The vasculature and inflammatory bowel disease: contribution to pathogenesis and clinical pathology, Inflamm Bowel Dis, vol.11, pp.304-317, 2005.

J. M. Robins, M. A. Hernan, and B. Brumback, Marginal structural models and causal inference in epidemiology, Epidemiology, pp.550-560, 2000.

G. R. Lichtenstein, B. G. Feagan, and R. D. Cohen, Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT TM registry, Am J Gastroenterol, vol.107, pp.1409-1431, 2012.

M. T. Osterman, W. J. Sandborn, and J. Colombel, Crohn's Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab, Am J Gastroenterol, vol.111, pp.1806-1815, 2016.

S. R. Cole and M. A. Hernán, Constructing Inverse Probability Weights for Marginal Structural Models, Am J Epidemiol, vol.168, pp.656-64, 2008.

C. Roubille, V. Richer, and T. Starnino, The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis, Ann Rheum Dis, vol.74, pp.480-489, 2015.

E. Arts, J. Fransen, and . Broeder-aa-den, The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients, Ann Rheum Dis, vol.74, pp.998-1003, 2015.

E. Myasoedova, A. Chandran, and B. Ilhan, The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease, Ann Rheum Dis, vol.75, pp.560-565, 2016.

M. Henriksen, J. Jahnsen, and I. Lygren, C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study, Gut, vol.57, pp.1518-1541, 2008.

P. M. Ridker, C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus, J Am Coll Cardiol, vol.49, pp.2129-2167, 2007.

R. Panaccione, J. Colombel, and W. J. Sandborn, Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE, Aliment Pharmacol Ther, vol.38, pp.1236-1283, 2013.

M. F. Neurath and S. Travis, Mucosal healing in inflammatory bowel diseases: a systematic review, Gut, vol.61, pp.1619-1654, 2012.

E. A. Fagan, R. F. Dyck, and P. N. Maton, Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis, Eur J Clin Invest, vol.12, pp.351-360, 1982.

V. Gross, T. Andus, and C. I. , Evidence for continuous stimulation of interleukin-6 production in Crohn's disease, Aliment Pharmacol Ther, vol.102, pp.1173-84, 1992.

S. Saibeni, M. Cattaneo, and M. Vecchi, Low Vitamin B6 Plasma Levels, a Risk Factor for Thrombosis, in Inflammatory Bowel Disease: Role of Inflammation and Correlation With Acute Phase Reactants, Am J Gastroenterol, vol.98, pp.112-119, 2003.

S. Galluzzo, G. Patti, and G. Dicuonzo, Association between NOD2/CARD15 polymorphisms and coronary artery disease: a case-control study, Hum Immunol, vol.72, pp.636-676, 2011.

J. P. Hugot, P. Laurent-puig, and C. Gower-rousseau, Mapping of a susceptibility locus for Crohn's disease on chromosome 16, Nature, vol.379, pp.821-824, 1996.

L. Tam, G. D. Kitas, and G. Ma, Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis?, Rheumatology, vol.53, pp.1108-1127, 2014.

C. M. Couris, S. Polazzi, and F. Olive, Breast cancer incidence using administrative data: correction with sensitivity and specificity, J Clin Epidemiol, vol.62, pp.660-666, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00428336

A. A. Chantry, C. Deneux-tharaux, and C. Cans, Hospital discharge data can be used for monitoring procedures and intensive care related to severe maternal morbidity, J Clin Epidemiol, vol.64, pp.1014-1036, 2011.
URL : https://hal.archives-ouvertes.fr/hal-02008104

Z. Uhry, L. Remontet, and M. Colonna, Cancer incidence estimation at a district level without a national registry: a validation study for 24 cancer sites using French health insurance and registry data, Cancer Epidemiol, vol.37, pp.99-114, 2013.

L. Lorgis, J. Cottenet, and G. Molins, Outcomes After Acute Myocardial Infarction in HIV-Infected Patients Analysis of Data From a French Nationwide Hospital Medical Information Database, Circulation, vol.127, pp.1767-74, 2013.

L. Sahli, M. Lapeyre-mestre, and H. Derumeaux, Positive predictive values of selected hospital discharge diagnoses to identify infections responsible for hospitalization in the French national hospital database, Pharmacoepidemiol Drug Saf, vol.25, pp.785-794, 2016.

M. Ng and D. S. Celermajer, Glucocorticoid treatment and cardiovascular disease, Heart, vol.90, p.829, 2004.

P. Seksik, I. Nion-larmurier, and H. Sokol, Effects of light smoking consumption on the clinical course of Crohn's disease, Inflamm Bowel Dis, vol.15, pp.734-775, 2009.

J. Cosnes, F. Carbonnel, and L. Beaugerie, Effects of cigarette smoking on the longterm course of Crohn's disease, Gastroenterology, vol.110, pp.424-455, 1996.

J. Cosnes, L. Beaugerie, and F. Carbonnel, Smoking cessation and the course of Crohn's disease: An intervention study, Gastroenterology, vol.120, pp.1093-1102, 2001.

L. Beaugerie, N. Massot, and F. Carbonnel, Impact of cessation of smoking on the course of ulcerative colitis, Am J Gastroenterol, vol.96, pp.2113-2119, 2001.

N. To, D. J. Gracie, and A. C. Ford, Systematic review with meta-analysis: the adverse effects of tobacco smoking on the natural history of Crohn's disease, Aliment Pharmacol Ther, vol.43, pp.549-61, 2016.

N. A. Molodecky, I. S. Soon, and D. M. Rabi, Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review, Gastroenterology, vol.142, pp.46-54, 2012.

, Age at cohort inclusion, mean (SD)

J. M. Robins, M. A. Hernan, and B. Brumback, Marginal structural models and causal inference in epidemiology, Epidemiology, pp.550-560, 2000.

S. R. Cole and M. A. Hernán, Constructing Inverse Probability Weights for Marginal Structural Models, Am J Epidemiol, vol.168, pp.656-64, 2008.

J. Cosnes, C. Gower-rousseau, and P. Seksik, Epidemiology and natural history of inflammatory bowel diseases, Gastroenterology, vol.140, pp.1785-94, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00631553

G. K. Hansson, Inflammation, atherosclerosis, and coronary artery disease, N Engl J Med, vol.352, pp.1685-1695, 2005.

J. A. Avina-zubieta, J. Thomas, and M. Sadatsafavi, Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies, Ann Rheum Dis, vol.71, pp.1524-1533, 2012.

L. Beaugerie, N. Brousse, and A. M. Bouvier, Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study, Lancet, vol.374, pp.1617-1642, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00466312

J. F. Colombel, W. J. Sandborn, and W. Reinisch, Infliximab, azathioprine, or combination therapy for Crohn's disease, N Engl J Med, vol.362, pp.1383-95, 2010.

R. Panaccione, S. Ghosh, and S. Middleton, Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis, Gastroenterology, vol.146, pp.392-400, 2014.

E. A. Fagan, R. F. Dyck, and P. N. Maton, Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis, Eur J Clin Invest, vol.12, pp.351-360, 1982.

S. H. Saverymuttu, H. J. Hodgson, and V. S. Chadwick, Differing acute phase responses in Crohn's disease and ulcerative colitis, Gut, vol.27, pp.809-822, 1986.

M. Henriksen, J. Jahnsen, and I. Lygren, C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study, Gut, vol.57, pp.1518-1541, 2008.

G. K. Hansson, Inflammation, atherosclerosis, and coronary artery disease, N Engl J Med, vol.352, pp.1685-95, 2005.

M. Peters, D. Symmons, and D. Mccarey, EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis, Ann Rheum Dis, vol.69, pp.325-356, 2010.

D. Symmons and S. E. Gabriel, Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE, Nat Rev Rheumatol, vol.7, pp.399-408, 2011.

C. Rungoe, S. Basit, and M. F. Ranthe, Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study, Gut, vol.62, pp.689-94, 2013.

P. Tuppin, L. De-roquefeuil, and A. Weill, French national health insurance information system and the permanent beneficiaries sample, Rev DÉpidémiologie Santé Publique, vol.58, pp.286-90, 2010.

. Atih, Agence technique de l'information sur l'hospitalisation. Programme de médicalisation des systèmes d'information (PMSI), présentation, 2015.

A. A. Chantry, C. Deneux-tharaux, and C. Cans, Hospital discharge data can be used for monitoring procedures and intensive care related to severe maternal morbidity, J Clin Epidemiol, vol.64, pp.1014-1036, 2011.
URL : https://hal.archives-ouvertes.fr/hal-02008104

L. Lorgis, J. Cottenet, and G. Molins, Outcomes After Acute Myocardial Infarction in HIV-Infected Patients Analysis of Data From a French Nationwide Hospital Medical Information Database, Circulation, vol.127, pp.1767-74, 2013.

K. Bouillon, M. Bertrand, and G. Maura, Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study, Lancet Haematol, vol.2, pp.150-159, 2015.

G. Maura, P. Blotière, and K. Bouillon, Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study, Circulation, vol.132, pp.1252-60, 2015.

M. Basson, M. Mezzarobba, and A. Weill, Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study, Gut, 2015.

L. Ginzburg and G. D. Oppenheimer, Non-Specific Granulomata of the Intestines: Inflammatory Tumors and Strictures of the Bowel, Ann Surg, vol.98, pp.1046-62, 1933.

N. A. Molodecky, I. S. Soon, and D. M. Rabi, Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review, Gastroenterology, vol.142, pp.46-54, 2012.

S. Ghione, H. Sarter, and M. Fumery, Dramatic Increase in Incidence of Ulcerative Colitis and Crohn's Disease (1988-2011): A Population-Based Study of French Adolescents, Am J Gastroenterol Published Online First, p.15, 2017.

C. S. Probert, V. Jayanthi, and A. O. Hughes, Prevalence and family risk of ulcerative colitis and Crohn's disease: an epidemiological study among Europeans and south Asians in Leicestershire, Gut, vol.34, pp.1547-51, 1993.

E. I. Benchimol, D. R. Mack, and A. Guttmann, Inflammatory bowel disease in immigrants to Canada and their children: a population-based cohort study, Am J Gastroenterol, vol.110, pp.553-63, 2015.

J. B. Kirsner, Historical origins of current IBD concepts, World J Gastroenterol, vol.7, pp.175-84, 2001.

G. G. Kaplan, The global burden of IBD: from 2015 to 2025, Nat Rev Gastroenterol Hepatol, vol.12, pp.720-727, 2015.

C. Gasche, J. Scholmerich, and J. Brynskov, A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Inflamm Bowel Dis, vol.6, pp.8-15, 1998.

T. Jess, M. Frisch, and J. Simonsen, Trends in Overall and Cause-Specific Mortality Among Patients With Inflammatory Bowel Disease From 1982 to 2010, Clin Gastroenterol Hepatol, vol.11, pp.43-51, 2013.

E. Langholz, P. Munkholm, and M. Davidsen, Changes in extent of ulcerative colitis: a study on the course and prognostic factors, Scand J Gastroenterol, vol.31, pp.260-266, 1996.

E. Langholz, P. Munkholm, and M. Davidsen, Course of ulcerative colitis: analysis of changes in disease activity over years, Gastroenterology, vol.107, pp.3-11, 1994.

E. Telakis and E. Tsironi, Indeterminate colitis-definition, diagnosis, characteristics and management, Ann Gastroenterol, vol.21, pp.173-180, 2009.

V. Gross, T. Andus, and C. I. , Evidence for continuous stimulation of interleukin-6 production in Crohn's disease, Gastroenterology, vol.102, pp.514-523, 1992.

S. P. Travis, J. M. Farrant, and C. Ricketts, Predicting outcome in severe ulcerative colitis, Gut, vol.38, pp.905-910, 1996.

M. Denis, C. Reenaers, and F. Fontaine, Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level, Inflamm Bowel Dis, vol.13, pp.1100-1105, 2007.

M. Jürgens, M. John, J. M. Cleynen, and I. , Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease, Clin Gastroenterol Hepatol, vol.9, pp.421-427, 2011.

D. T. Rubin, D. Huo, and J. A. Kinnucan, Inflammation Is an Independent Risk Factor for Colonic Neoplasia in Patients With Ulcerative Colitis: A Case-Control Study, Clin Gastroenterol Hepatol, vol.11, pp.1601-1608, 2013.

L. Beaugerie and S. Itzkowitz, Cancers Complicating Inflammatory Bowel Disease, N Engl J Med, vol.372, pp.1441-52, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01301711

J. Cosnes, F. Carbonnel, and L. Beaugerie, Effects of cigarette smoking on the longterm course of Crohn's disease, Gastroenterology, vol.110, pp.424-455, 1996.

J. Cosnes, L. Beaugerie, and F. Carbonnel, Smoking cessation and the course of Crohn's disease: An intervention study, Gastroenterology, vol.120, pp.1093-1102, 2001.

L. Beaugerie, N. Massot, and F. Carbonnel, Impact of cessation of smoking on the course of ulcerative colitis, Am J Gastroenterol, vol.96, pp.2113-2119, 2001.

N. N. Andersen, S. Gørtz, and M. Frisch, Reduced risk of UC in families affected by appendicitis: a Danish national cohort study, Gut, 2016.

C. Ott and J. Schölmerich, Extraintestinal manifestations and complications in IBD, Nat Rev Gastroenterol Hepatol, vol.10, pp.585-95, 2013.

I. E. Koutroubakis, Therapy insight: Vascular complications in patients with inflammatory bowel disease, Nat Clin Pract Gastroenterol Hepatol, vol.2, pp.266-72, 2005.

M. J. Grainge, J. West, and T. R. Card, Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study, Lancet, vol.375, pp.657-63, 2010.

M. Harbord, V. Annese, and S. R. Vavricka, The First European Evidence-Based Consensus on Extra-Intestinal Manifestations in Inflammatory Bowel Disease, J Crohns Colitis, p.213, 2015.

W. A. Bemelman, J. Warusavitarne, and G. M. Sampietro, ECCO-ESCP Consensus on Surgery for Crohn's Disease, J Crohns Colitis Published Online First, issue.11, 2017.

Y. Wang, C. E. Parker, and T. Bhanji, Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev Published Online First: 21, 2016.

Y. Wang, C. E. Parker, and B. G. Feagan, Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis, Cochrane Database Syst Rev Published Online First, 2016.

W. Lim, Y. Wang, and J. K. Macdonald, Aminosalicylates for induction of remission or response in Crohn's disease, Cochrane Database Syst Rev, vol.7, p.8870, 2016.

V. Patel, Y. Wang, and J. K. Macdonald, Methotrexate for maintenance of remission in Crohn's disease, Cochrane Database Syst Rev, p.6884, 2014.

M. Lémann, J. Mary, and J. Colombel, Double-Blind, Controlled Withdrawal Trial in Crohn's Disease Patients in Long-term Remission on Azathioprine, Gastroenterology, vol.128, pp.1812-1820, 2005.

E. Louis, J. Mary, and G. Vernier-massouille, Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped, Gastroenterology, vol.142, pp.63-70, 2012.

A. G. Fraser, T. R. Orchard, and D. P. Jewell, The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review, Gut, vol.50, pp.485-494, 2002.

E. Prefontaine, L. R. Sutherland, and J. K. Macdonald, Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease, Cochrane Database Syst Rev, vol.1, p.67, 2009.

A. Timmer, J. Mcdonald, and D. J. Tsoulis, Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis, Cochrane Database Syst Rev, vol.9, p.478, 2012.

M. Gordon, K. Taylor, and A. K. Akobeng, Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease, Cochrane Database Syst Rev, vol.8, p.10233, 2014.

N. A. Kennedy, E. Rhatigan, and I. Arnott, A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis, Aliment Pharmacol Ther, vol.38, pp.1255-66, 2013.

J. P. Gisbert and F. Gomolln, Thiopurine-Induced Myelotoxicity in Patients With Inflammatory Bowel Disease: A Review, Am J Gastroenterol, vol.103, pp.1783-800, 2008.

J. P. Gisbert, Y. González-lama, and J. Maté, Thiopurine-Induced Liver Injury in Patients With Inflammatory Bowel Disease: A Systematic Review, Am J Gastroenterol, vol.102, pp.1518-1545, 2007.

M. C. Dubinsky, E. A. Vasiliauskas, and H. Singh, 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients, Gastroenterology, vol.125, pp.298-303, 2003.

G. R. Lichtenstein, P. Rutgeerts, and W. J. Sandborn, A pooled analysis of infections, malignancy, and mortality in infliximab-and immunomodulator-treated adult patients with inflammatory bowel disease, Am J Gastroenterol, vol.107, pp.1051-63, 2012.

M. Toruner, E. V. Loftus, and W. S. Harmsen, Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease, Gastroenterology, vol.134, pp.929-965, 2008.

J. F. Rahier, F. Magro, and C. Abreu, Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease, J Crohns Colitis, vol.8, pp.443-68, 2014.

L. Peyrin-biroulet, K. Khosrotehrani, and F. Carrat, Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease, Gastroenterology, vol.141, pp.1-5, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00631539

A. Lopez, M. Mounier, and A. Bouvier, Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease, Clin Gastroenterol Hepatol, vol.12, pp.1324-1333, 2014.
URL : https://hal.archives-ouvertes.fr/hal-00955200

A. Bourrier, F. Carrat, and J. Colombel, Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study, Aliment Pharmacol Ther Published Online First, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02013807

D. S. Kotlyar, J. D. Lewis, and L. Beaugerie, Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis, Clin Gastroenterol Hepatol, vol.13, pp.847-858, 2015.
URL : https://hal.archives-ouvertes.fr/hal-00998407

M. D. Long, C. F. Martin, and C. A. Pipkin, Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease, Gastroenterology, vol.143, pp.390-399, 2012.

S. R. Targan, S. B. Hanauer, and S. J. Van-deventer, A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group, N Engl J Med, vol.337, pp.1029-1064, 1997.

S. B. Hanauer, W. J. Sandborn, and P. Rutgeerts, Human Anti-Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn's Disease: the CLASSIC-I Trial, Gastroenterology, vol.130, pp.323-356, 2006.

E. J. Eshuis, C. P. Peters, and A. A. Van-bodegraven, Ten years of infliximab for Crohn's disease: outcome in 469 patients from 2 tertiary referral centers, Inflamm Bowel Dis, vol.19, pp.1622-1652, 2013.

M. Chaparro, J. Panés, and V. García, Long-term durability of response to adalimumab in Crohn?s disease, Inflamm Bowel Dis, vol.18, pp.685-90, 2012.

H. Fidder, F. Schnitzler, and M. Ferrante, Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study, Gut, vol.58, pp.501-509, 2009.

I. Cleynen, W. Van-moerkercke, and T. Billiet, Characteristics of Skin Lesions Associated With Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease: A Cohort Study, Ann Intern Med, vol.164, p.10, 2016.

N. Andersen, N. Pasternak, B. Friis-møller, and N. , Association between tumour necrosis factor-? inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study, BMJ, vol.350, p.2809, 2015.

C. A. Siegel, S. M. Marden, and S. M. Persing, Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis, Clin Gastroenterol Hepatol, vol.7, pp.874-81, 2009.

L. J. Herrinton, L. Liu, and X. Weng, Role of Thiopurine and Anti-TNF Therapy in Lymphoma in Inflammatory Bowel Disease, Am J Gastroenterol, vol.106, pp.2146-53, 2011.

J. Colombel, W. Reinisch, and G. J. Mantzaris, Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's diseasea SONIC post hoc analysis, Aliment Pharmacol Ther, vol.41, pp.734-780, 2015.

J. M. Chalhoub, H. H. Rimmani, and V. V. Gumaste, Systematic Review and Metaanalysis: Adalimumab Monotherapy Versus Combination Therapy with Immunomodulators for Induction and Maintenance of Remission and Response in Patients with Crohn's Disease, Inflamm Bowel Dis, vol.23, pp.1316-1343, 2017.

B. G. Feagan, J. Mcdonald, and R. Panaccione, Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease, Gastroenterology, vol.146, pp.681-688, 2014.

S. Bonovas, G. Fiorino, and M. Allocca, Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis, Clin Gastroenterol Hepatol, vol.14, pp.1385-1397, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01659116

G. R. Lichtenstein, B. G. Feagan, and R. D. Cohen, Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT TM registry, Am J Gastroenterol, vol.107, pp.1409-1431, 2012.

C. G. Grijalva, L. Chen, and E. Delzell, Initiation of Tumor Necrosis Factor-? Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases, JAMA, vol.306, 2011.

Z. Lin, Y. Bai, and P. Zheng, Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn's disease, Eur J Gastroenterol Hepatol, vol.23, pp.1100-1110, 2011.

G. R. Lichtenstein, R. H. Diamond, and C. L. Wagner, Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials, Aliment Pharmacol Ther, vol.30, pp.210-236, 2009.

M. T. Osterman, W. J. Sandborn, and J. Colombel, Crohn's Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab, Am J Gastroenterol, vol.111, pp.1806-1815, 2016.

M. T. Osterman, K. Haynes, and E. Delzell, Effectiveness and Safety of Immunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's Disease, Clin Gastroenterol Hepatol, vol.13, pp.1293-1301, 2015.

, Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study, GBD 2013 Mortality and Causes of Death Collaborators, vol.385, pp.117-71, 2013.

, European Cardiovascular Disease Statistics, issue.4, 2017.

A. E. Moran, M. H. Forouzanfar, and G. A. Roth, The Global Burden of Ischemic Heart Disease in 1990 and 2010 The Global Burden of Disease, Study. Circulation, vol.129, pp.1493-501, 2010.

V. L. Feigin, M. H. Forouzanfar, and R. Krishnamurthi, Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study, The Lancet, vol.383, pp.245-255, 2010.

R. Beaglehole and R. Bonita, Global public health: a scorecard, The Lancet, vol.372, pp.1988-1996, 2008.

K. Thygesen, J. S. Alpert, and A. S. Jaffe, Third Universal Definition of Myocardial Infarction, Circulation, vol.126, pp.2020-2055, 2012.

, The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators, J Clin Epidemiol, vol.41, pp.105-119, 1988.

E. J. Benjamin, M. J. Blaha, and S. E. Chiuve, Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association, Circulation, 2017.

F. Fowkes, V. Aboyans, and F. Fowkes, Peripheral artery disease: epidemiology and global perspectives, Nat Rev Cardiol, vol.14, pp.156-70, 2017.

L. Norgren, W. R. Hiatt, and J. A. Dormandy, Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II), J Vasc Surg, vol.45, pp.5-67, 2007.

W. B. Kannel, T. R. Dawber, and A. Kagan, Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study, Ann Intern Med, vol.55, pp.33-50, 1961.

T. R. Dawber, F. E. Moore, and G. V. Mann, Coronary heart disease in the Framingham study, Am J Public Health Nations Health, vol.47, pp.4-24, 1957.

R. W. Alexander, Hypertension and the Pathogenesis of Atherosclerosis: Oxidative Stress and the Mediation of Arterial Inflammatory Response: A New Perspective, Hypertension, vol.25, pp.155-61, 1995.

W. B. Kannel, Blood pressure as a cardiovascular risk factor: prevention and treatment, JAMA, vol.275, pp.1571-1577, 1996.

G. Mancia, R. Fagard, and K. Narkiewicz, ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), J Hypertens, vol.31, pp.1281-357, 2013.
URL : https://hal.archives-ouvertes.fr/hal-02042310

A. Keys and F. Fidanza, Serum cholesterol and relative body weight of coronary patients in different populations, Circulation, vol.22, pp.1091-106, 1960.

T. Gordon, W. P. Castelli, and M. C. Hjortland, High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study, Am J Med, vol.62, pp.707-721, 1977.

P. Amarenco, J. Labreuche, and P. Touboul, High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review, Atherosclerosis, vol.196, pp.489-96, 2008.

R. Dubroff, Cholesterol confusion and statin controversy, World J Cardiol, vol.7, p.404, 2015.

S. M. Grundy, I. J. Benjamin, and G. L. Burke, Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association, Circulation, vol.100, pp.1134-1180, 1999.

G. K. Kolluru, S. C. Bir, and C. G. Kevil, Endothelial Dysfunction and Diabetes: Effects on Angiogenesis, Vascular Remodeling, and Wound Healing, Int J Vasc Med, 2012.

, International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome, p.31

. Aug2017,

V. Z. Rocha and P. Libby, Obesity, inflammation, and atherosclerosis, Nat Rev Cardiol, vol.6, pp.399-409, 2009.

J. A. Ambrose and R. S. Barua, The pathophysiology of cigarette smoking and cardiovascular disease, J Am Coll Cardiol, vol.43, pp.1731-1738, 2004.

J. Rehm, C. T. Sempos, and M. Trevisan, Alcohol and cardiovascular disease--more than one paradox to consider. Average volume of alcohol consumption, patterns of drinking and risk of coronary heart disease--a review, J Cardiovasc Risk, vol.10, pp.15-20, 2003.

P. Jousilahti, E. Vartiainen, and J. Tuomilehto, Cardiovascular Risk Factors, and Coronary Heart Disease: A Prospective Follow-Up Study, vol.14, p.786

, Middle-Aged Men and Women in Finland, Circulation, vol.99, pp.1165-72, 1999.

W. P. Castelli, Epidemiology of coronary heart disease: the Framingham study, Am J Med, vol.76, pp.4-12, 1984.

H. Schunkert, I. R. König, and S. Kathiresan, Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease, Nat Genet, vol.43, pp.333-341, 2011.

P. Libby and G. K. Hansson, Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions, Lab Investig J Tech Methods Pathol, vol.64, pp.5-15, 1991.

F. K. Swirski, M. J. Pittet, and M. F. Kircher, Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease, Proc Natl Acad Sci, vol.103, pp.10340-10345, 2006.

P. Libby and G. Shi, Mast cells as mediators and modulators of atherogenesis, Circulation, vol.115, pp.2471-2474, 2007.

D. A. Morrow, Y. Wang, and K. Croce, Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial, Am Heart J, vol.155, pp.49-55, 2008.

J. Frostegård, A. K. Ulfgren, and P. Nyberg, Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines, Atherosclerosis, vol.145, pp.33-43, 1999.

K. Shimizu, M. Shichiri, and P. Libby, Th2-predominant inflammation and blockade of IFN-gamma signaling induce aneurysms in allografted aortas, J Clin Invest, vol.114, pp.300-308, 2004.

G. Caligiuri, A. Nicoletti, and B. Poirier, Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice, J Clin Invest, vol.109, pp.745-53, 2002.

G. E. Mckellar, D. W. Mccarey, and N. Sattar, Role for TNF in atherosclerosis? Lessons from autoimmune disease, Nat Rev Cardiol, vol.6, p.57, 2009.

L. C. Battes, J. M. Cheng, and R. M. Oemrawsingh, Circulating cytokines in relation to the extent and composition of coronary atherosclerosis: results from the ATHEROREMO-IVUS study, Atherosclerosis, vol.236, pp.18-24, 2014.

P. M. Ridker, C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus, J Am Coll Cardiol, vol.49, pp.2129-2167, 2007.

A. Shankar, J. Li, and F. J. Nieto, Association between C-reactive protein level and peripheral arterial disease among US adults without cardiovascular disease, diabetes, or hypertension, Am Heart J, vol.154, pp.495-501, 2007.

S. Skeoch and I. N. Bruce, Atherosclerosis in rheumatoid arthritis: is it all about inflammation?, Nat Rev Rheumatol, vol.11, pp.390-400, 2015.

S. Wållberg-jonsson, K. Caidahl, and N. Klintland, Increased arterial stiffness and indication of endothelial dysfunction in long-standing rheumatoid arthritis, Scand J Rheumatol, vol.37, pp.1-5, 2008.

C. Charles-schoeman, Y. Y. Lee, and V. Grijalva, Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis, Ann Rheum Dis, vol.71, pp.1157-62, 2012.

J. Robertson, M. J. Peters, and I. B. Mcinnes, Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm, Nat Rev Rheumatol, vol.9, pp.513-536, 2013.

S. Cobb, F. Anderson, and W. Bauer, Length of life and cause of death in rheumatoid arthritis, N Engl J Med, vol.249, pp.553-559, 1953.

D. H. Solomon, N. J. Goodson, and J. N. Katz, Patterns of cardiovascular risk in rheumatoid arthritis, Ann Rheum Dis, vol.65, pp.1608-1620, 2006.

J. Lindhardsen, O. Ahlehoff, and G. H. Gislason, The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study, Ann Rheum Dis, vol.70, pp.929-963, 2011.

M. E. Holmqvist, S. Wedrén, and L. Jacobsson, No increased occurrence of ischemic heart disease prior to the onset of rheumatoid arthritis: results from two Swedish population-based rheumatoid arthritis cohorts, Arthritis Rheum, vol.60, pp.2861-2870, 2009.

E. Arts, J. Fransen, and . Broeder-aa-den, The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients, Ann Rheum Dis, vol.74, pp.998-1003, 2015.

E. Myasoedova, A. Chandran, and B. Ilhan, The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease, Ann Rheum Dis, vol.75, pp.560-565, 2016.

C. Roubille, V. Richer, and T. Starnino, The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis, Ann Rheum Dis, vol.74, pp.480-489, 2015.

A. A. Manfredi, M. Baldini, and M. Camera, Anti-TNF? agents curb platelet activation in patients with rheumatoid arthritis, Ann Rheum Dis, p.2015, 2016.

L. Tam, G. D. Kitas, and G. Ma, Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis?, Rheumatology, vol.53, pp.1108-1127, 2014.

S. Mathieu, B. Pereira, and M. Soubrier, Cardiovascular events in ankylosing spondylitis: An updated meta-analysis, Semin Arthritis Rheum, vol.44, pp.551-556, 2015.

A. Ogdie, Y. Yu, and K. Haynes, Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study, Ann Rheum Dis, vol.74, pp.326-358, 2015.

R. Agca, S. C. Heslinga, and S. Rollefstad, EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update, Ann Rheum Dis, vol.76, pp.17-28, 2017.

D. H. Solomon, J. Kremer, and J. R. Curtis, Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity, Ann Rheum Dis, vol.69, pp.1920-1925, 2010.

K. P. Liao and D. H. Solomon, Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis, Rheumatology, vol.52, pp.45-52, 2013.

E. Arts, C. Popa, and A. Broeder, Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis, Ann Rheum Dis, vol.74, pp.668-74, 2015.

E. Arts, C. D. Popa, and A. Broeder, Prediction of cardiovascular risk in rheumatoid arthritis: performance of original and adapted SCORE algorithms, Ann Rheum Dis, vol.75, pp.674-80, 2016.

M. B. Urowitz, A. A. Bookman, and B. E. Koehler, The bimodal mortality pattern of systemic lupus erythematosus, Am J Med, vol.60, pp.221-226, 1976.

L. Björnådal, L. Yin, and F. Granath, Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95, J Rheumatol, vol.31, pp.713-722, 2004.

E. V. Arkema, E. Svenungsson, V. Euler, and M. , Stroke in systemic lupus erythematosus: a Swedish population-based cohort study, Ann Rheum Dis, vol.76, pp.1544-1553, 2017.

J. M. Esdaile, M. Abrahamowicz, and T. Grodzicky, Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus, Arthritis Rheum, vol.44, pp.2331-2338, 2001.

S. Singh, I. J. Kullo, and D. S. Pardi, Epidemiology, risk factors and management of cardiovascular diseases in IBD, Nat Rev Gastroenterol Hepatol Published Online First, 2014.

G. Wu, R. Leng, and Q. Lu, Subclinical Atherosclerosis in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis, Angiology, p.000331971665203, 2016.

L. Zanoli, M. Cannavò, and S. Rastelli, Arterial stiffness is increased in patients with inflammatory bowel disease, J Hypertens, vol.30, pp.1775-81, 2012.

I. Roifman, Y. C. Sun, and J. P. Fedwick, Evidence of endothelial dysfunction in patients with inflammatory bowel disease, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc, vol.7, pp.175-82, 2009.

K. Kume, M. Yamasaki, and M. Tashiro, Activations of coagulation and fibrinolysis secondary to bowel inflammation in patients with ulcerative colitis, Intern Med Tokyo Jpn, vol.46, pp.1323-1332, 2007.

G. Davì and C. Patrono, Platelet Activation and Atherothrombosis, N Engl J Med, vol.357, pp.2482-94, 2007.

S. Danese, J. A. Katz, and S. Saibeni, Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients, Gut, vol.52, pp.1435-1476, 2003.

O. A. Hatoum and D. G. Binion, The vasculature and inflammatory bowel disease: contribution to pathogenesis and clinical pathology, Inflamm Bowel Dis, vol.11, pp.304-317, 2005.

A. Oussalah, J. Guéant, P. , and L. , Meta-analysis: hyperhomocysteinaemia in inflammatory bowel diseases, Aliment Pharmacol Ther, vol.34, pp.1173-84, 2011.

S. Saibeni, M. Cattaneo, and M. Vecchi, Low Vitamin B6 Plasma Levels, a Risk Factor for Thrombosis, in Inflammatory Bowel Disease: Role of Inflammation and Correlation With Acute Phase Reactants, Am J Gastroenterol, vol.98, pp.112-119, 2003.

S. Galluzzo, G. Patti, and G. Dicuonzo, Association between NOD2/CARD15 polymorphisms and coronary artery disease: a case-control study, Hum Immunol, vol.72, pp.636-676, 2011.

J. P. Hugot, P. Laurent-puig, and C. Gower-rousseau, Mapping of a susceptibility locus for Crohn's disease on chromosome 16, Nature, vol.379, pp.821-824, 1996.

B. Chassaing and A. Darfeuille-michaud, The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases, Gastroenterology, vol.140, pp.1720-1728, 2011.

Z. Wang, E. Klipfell, and B. J. Bennett, Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease, Nature, vol.472, pp.57-63, 2011.

C. N. Bernstein, A. Wajda, and J. F. Blanchard, The Incidence of Arterial Thromboembolic Diseases in Inflammatory Bowel Disease: A Population-Based Study, Clin Gastroenterol Hepatol, vol.6, pp.41-46, 2008.

A. J. Yarur, A. R. Deshpande, and D. M. Pechman, Inflammatory Bowel Disease Is Associated With an Increased Incidence of Cardiovascular Events, Am J Gastroenterol, vol.106, pp.741-748, 2011.

C. Ha, S. Magowan, and N. A. Accortt, Risk of Arterial Thrombotic Events in Inflammatory Bowel Disease, Am J Gastroenterol, vol.104, pp.1445-51, 2009.

S. Singh, H. Singh, and L. Ev, Risk of Cerebrovascular Accidents and Ischemic Heart Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis, Clin Gastroenterol Hepatol, vol.12, pp.382-393, 2014.

M. Fumery, C. Xiaocang, and L. Dauchet, Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: A meta-analysis of observational studies, J Crohns Colitis, vol.8, pp.469-79, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01699623

A. Sridhar, S. Parasa, and U. Navaneethan, Comprehensive study of cardiovascular morbidity in hospitalized inflammatory bowel disease patients, J Crohns Colitis, vol.5, pp.287-94, 2011.

J. J. Keller, J. Wang, and Y. Hwang, Increased risk of stroke among patients with Crohn's disease: a population-based matched cohort study, Int J Colorectal Dis, vol.30, pp.645-53, 2015.

C. E. Collins, D. S. Rampton, and J. Rogers, Platelet aggregation and neutrophil sequestration in the mesenteric circulation in inflammatory bowel disease, Eur J Gastroenterol Hepatol, vol.9, pp.1213-1220, 1997.

S. Inamdar, S. Altafi, and K. Sultan, Tu1285 Increased Risk of Coronary Artery Disease Among Patients With Inflammatory Bowel Disease, Gastroenterology, vol.142, 2012.

S. L. Kristensen, O. Ahlehoff, and J. Lindhardsen, Disease Activity in Inflammatory Bowel Disease Is Associated with Increased Risk of Myocardial Infarction, Stroke and Cardiovascular Death -A Danish Nationwide Cohort Study, PloS One, vol.8, p.56944, 2013.

M. T. Osterman, Y. Yang, and C. Brensinger, Increased Risk of Myocardial Infarction Among Patients With Ulcerative Colitis or Crohn's Disease, Clin Gastroenterol Hepatol, vol.9, pp.875-80, 2011.

F. Andersohn, M. Waring, and E. Garbe, Risk of ischemic stroke in patients with Crohn's disease: a population-based nested case-control study, Inflamm Bowel Dis, vol.16, pp.1387-92, 2010.

M. Fumery, A. G. Singh, and R. Khera, Biologic Therapy and Immunodulators are Associated with Decreased Risk of Cardiovascular Events in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis, Gastroenterology, vol.152, p.77, 2017.

, Diagnosis-related groups in Europe: moving towards transparency, efficiency and quality in hospitals, 2011.

, Tableau des molécules onéreuses et dispositifs médicaux implantables de la liste en sus -Data

. Insee, Répartition des décès selon le lieu du décès [Distribution of deaths according to location]: Institut national de la statistique et des études économiques, p.28, 2014.

L. Remontet, N. Mitton, and C. M. Couris, Is it possible to estimate the incidence of breast cancer from medico-administrative databases?, Eur J Epidemiol, vol.23, pp.681-689, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00338952

Z. Uhry, L. Remontet, and M. Colonna, Cancer incidence estimation at a district level without a national registry: a validation study for 24 cancer sites using French health insurance and registry data, Cancer Epidemiol, vol.37, pp.99-114, 2013.

L. Sahli, M. Lapeyre-mestre, and H. Derumeaux, Positive predictive values of selected hospital discharge diagnoses to identify infections responsible for hospitalization in the French national hospital database, Pharmacoepidemiol Drug Saf, vol.25, pp.785-794, 2016.

M. Giroud, M. Hommel, and E. Benzenine, Positive Predictive Value of French Hospitalization Discharge Codes for Stroke and Transient Ischemic Attack, Eur Neurol, vol.74, pp.92-101, 2015.

F. Raguideau, M. Lemaitre, and R. Dray-spira, Association Between Oral Fluoroquinolone Use and Retinal Detachment, JAMA Ophthalmol, vol.134, p.415, 2016.

J. Kirchgesner, M. Lemaitre, and A. Rudnichi, Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases, Aliment Pharmacol Ther, vol.45, pp.37-49, 2009.

J. M. Robins, M. A. Hernan, and B. Brumback, Marginal structural models and causal inference in epidemiology, Epidemiology, pp.550-560, 2000.

R. Panaccione, J. Colombel, and W. J. Sandborn, Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE, Aliment Pharmacol Ther, vol.38, pp.1236-1283, 2013.

M. F. Neurath and S. Travis, Mucosal healing in inflammatory bowel diseases: a systematic review, Gut, vol.61, pp.1619-1654, 2012.

M. Ng and D. S. Celermajer, Glucocorticoid treatment and cardiovascular disease, Heart, vol.90, p.829, 2004.

L. Beaugerie, M. Svrcek, and P. Seksik, Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease, Gastroenterology, vol.145, pp.166-175, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00806654

D. G. Altman and P. K. Andersen, Calculating the number needed to treat for trials where the outcome is time to an event, BMJ, vol.319, pp.1492-1497, 1999.

N. Berthier, R. Guignard, and J. Richard, Regional comparison of tobacco smoking and e-cigarette use in France in 2014, Bull Epidémiol Hebd, pp.508-522, 2016.

P. Seksik, I. Nion-larmurier, and H. Sokol, Effects of light smoking consumption on the clinical course of Crohn's disease, Inflamm Bowel Dis, vol.15, pp.734-775, 2009.

J. Kirchgesner, L. Beaugerie, and F. Carrat, Impact on Life Expectancy of Withdrawing Thiopurines in Patients with Crohn's Disease in Sustained Clinical Remission: A Lifetime Risk-Benefit Analysis, PloS One, vol.11, p.157191, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01332387